Skip to content
Subscriber Only

SoftBank's Vision Fund Courts Startups That Mix Data and Pharma

  • Fund invests in Roivant Sciences in $1.1 billion round
  • London-based BenevolentAI also said to be target for SoftBank
Video player cover image

SoftBank's Masayoshi Son Seeks Disruptive Investments

SoftBank Group Corp.’s Vision Fund is targeting a range of investments in startups that use data to help speed up drug discovery, as the near-$100 billion fund continues its deal spree.

Anglo-Swiss pharmaceutical group Roivant Sciences Ltd., said Wednesday it had raised $1.1 billion from investors, led by the Vision Fund, to start new subsidiaries.